RadioBDC Logo
The Cave | Mumford & Sons Listen Live
THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING
MASS. MOVERS

Amag cleared to sell drug in Canada

Brian Pereira left the CEO’s job last month after Amag shareholders voted down the acquisition of Allos Therapeutics Inc. Brian Pereira left the CEO’s job last month after Amag shareholders voted down the acquisition of Allos Therapeutics Inc.
December 13, 2011
Text size +
  • E-mail
  • E-mail this article

    Invalid E-mail address
    Invalid E-mail address

    Sending your article

    Your article has been sent.

Amag Pharmaceuticals Inc. said Monday its iron deficiency treatment Feraheme received regulatory approval in Canada, and the company will get a $3 million milestone payment when commercial sales start there. Japanese drugmaker Takeda Pharmaceutical Co. Ltd. has an exclusive license to sell the drug in Canada. Feraheme treats iron deficiency anemia in adults with chronic kidney disease, and it has been available in the United States for more than two years. Amag, based in Lexington, Mass., also is seeking approval to sell the drug in Europe.

For more from BostonGlobe.com, sign up or log in below

To continue, please sign up or log in to BostonGlobe.com

Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com

Sign up

Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.

Are you a Boston Globe home delivery subscriber?

Get FREE access as part of your print subscription.

BostonGlobe.com subscriber

Click to continue reading this article or to log in to BostonGlobe.com.
  • E-mail
  • E-mail this article

    Invalid E-mail address
    Invalid E-mail address

    Sending your article

    Your article has been sent.